Titan Pharmaceuticals, Inc.

Navigate Titan Pharmaceuticals, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Careers
  • News
    • Overview
    • Press Releases
    • Events
    • Presentations
    • In the News
    • Media Resources
  • Investors
    • Overview
    • News / Events
    • Company Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact
  • Search
  • Twitter

Press Releases

  • Home
  • News
  • Press Releases
News

Navigate News

  • Overview
  • Press Releases
  • Events
  • Presentations
  • In the News
  • Media Resources

Press Releases

  • All News
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009

Positive Early Study Results Help Pave Wave for Titan Pharmaceuticals to Move Forward with its JT-09 ProNeura® Development Program

February 1, 2021

Titan Pharmaceuticals Announces Pricing of $9.7 Million Registered Direct Offering

January 15, 2021

Titan Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements

December 16, 2020

Titan Pharmaceuticals Announces Reverse Stock Split

November 30, 2020

Titan Pharmaceuticals Reports Third Quarter 2020 Financial Results

November 16, 2020

Titan Pharmaceuticals Completes Debt Settlement With Molteni And Horizon & Acquisiton Of JT Pharma's Kappa Opioid Agonist Peptide, JT-09

November 2, 2020

Titan Pharmaceuticals Announces Pricing of $8.0 Million Underwritten Public Offering

October 28, 2020

Titan Pharmaceuticals Enters Into Definitive Agreement To Acquire JT Pharma's Kappa Opioid Agonist Peptide, JT-09

October 28, 2020

Titan Pharmaceuticals Announces Debt Settlement Agreement with Molteni and Horizon

October 26, 2020

Titan Pharmaceuticals Provides a Strategic & Corporate Update

October 15, 2020

  • « Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...25
  • Next »
© 2025 Titan Pharmaceuticals, Inc. All Rights Reserved.
Privacy Policy Titan FCOI Policy Disclaimer Sitemap Twitter